Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC.

Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, Wendel HG, Dogan S, Tamarapu PP, Blenis J, Ghossein R, Knauf JA, Rätsch G, Fagin JA.

Cancer Discov. 2018 Oct 10. pii: CD-18-0606. doi: 10.1158/2159-8290.CD-18-0606. [Epub ahead of print]

PMID:
30305285
2.

Current treatment strategies in metastasized differentiated thyroid cancer.

Kreissl M, Janssen M, Nagarajah J.

J Nucl Med. 2018 Sep 6. pii: jnumed.117.190819. doi: 10.2967/jnumed.117.190819. [Epub ahead of print]

PMID:
30190306
3.

Quantitative performance of 124I PET/MR of neck lesions in thyroid cancer patients using 124I PET/CT as reference.

Jentzen W, Phaosricharoen J, Gomez B, Hetkamp P, Stebner V, Binse I, Kinner S, Herrmann K, Sabet A, Nagarajah J.

EJNMMI Phys. 2018 Jul 19;5(1):13. doi: 10.1186/s40658-018-0214-y.

4.

[Somatostatin receptor PET/CT (SSTR-PET/CT)].

Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A.

Nuklearmedizin. 2018 Feb;57(1):4-17. doi: 10.1055/s-0038-1636560. Epub 2018 Feb 21. German.

PMID:
29536494
5.

Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities.

Ruhlmann M, Sonnenschein W, Nagarajah J, Binse I, Herrmann K, Jentzen W.

Nucl Med Commun. 2018 May;39(5):457-464. doi: 10.1097/MNM.0000000000000817.

PMID:
29517576
6.

Diagnostic accuracy of 18F-FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma.

Ruhlmann V, Poeppel TD, Veit J, Nagarajah J, Umutlu L, Hoffmann TK, Bockisch A, Herrmann K, Sauerwein W.

BMC Cancer. 2017 Dec 22;17(1):887. doi: 10.1186/s12885-017-3890-4.

7.

Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.

Tesselaar MH, Crezee T, Schuurmans I, Gerrits D, Nagarajah J, Boerman OC, van Engen-van Grunsven I, Smit JWA, Netea-Maier RT, Plantinga TS.

J Nucl Med. 2018 May;59(5):780-786. doi: 10.2967/jnumed.117.200675. Epub 2017 Dec 14.

PMID:
29242405
8.

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.

Tesselaar MH, Smit JW, Nagarajah J, Netea-Maier RT, Plantinga TS.

J Mol Endocrinol. 2017 Nov;59(4):R141-R154. doi: 10.1530/JME-17-0134. Epub 2017 Sep 20. Review.

PMID:
28931558
9.

Iodine Symporter Targeting with 124I/131I Theranostics.

Nagarajah J, Janssen M, Hetkamp P, Jentzen W.

J Nucl Med. 2017 Sep;58(Suppl 2):34S-38S. doi: 10.2967/jnumed.116.186866. Review.

10.

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA.

J Clin Invest. 2016 Nov 1;126(11):4119-4124. doi: 10.1172/JCI89067. Epub 2016 Sep 26.

11.

Serum Thyroglobulin Doubling Time in Progressive Thyroid Cancer.

Rössing RM, Jentzen W, Nagarajah J, Bockisch A, Görges R.

Thyroid. 2016 Dec;26(12):1712-1718. Epub 2016 Nov 9.

PMID:
27750024
12.

Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.

Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J, Umutlu L, Antoch G, Kinner S.

Eur J Radiol. 2016 Feb;85(2):459-65. doi: 10.1016/j.ejrad.2015.12.010. Epub 2015 Dec 19.

PMID:
26781152
13.

Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging.

Jentzen W, Richter M, Nagarajah J, Poeppel TD, Brandau W, Dawes C, Bockisch A, Binse I.

EJNMMI Phys. 2014 Dec;1(1):100. doi: 10.1186/s40658-014-0100-1. Epub 2014 Dec 6.

14.

Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.

Grueneisen J, Nagarajah J, Buchbender C, Hoffmann O, Schaarschmidt BM, Poeppel T, Forsting M, Quick HH, Umutlu L, Kinner S.

Invest Radiol. 2015 Aug;50(8):505-13. doi: 10.1097/RLI.0000000000000197.

PMID:
26115367
15.

Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.

Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK.

J Nucl Med. 2015 May;56(5):662-7. doi: 10.2967/jnumed.114.150607. Epub 2015 Mar 26.

16.

[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)].

Poeppel TD, Boy C, Bockisch A, Kotzerke J, Buchmann I, Ezziddin S, Scheidhauer K, Krause BJ, Schmidt D, Amthauer H, Rösch F, Nagarajah J, Führer D, Lahner H, Pöpperl G, Hörsch D, Walter MA, Baum RP.

Nuklearmedizin. 2015;54(1):1-11; quiz N2. German.

PMID:
25683107
17.

Impact of dual-energy CT prior to radioembolization (RE).

Altenbernd JC, von der Stein I, Wetter A, Nagarajah J, Umutlu L, Heusner T, Theysohn JM, Ringelstein A, Forsting M, Lauenstein T.

Acta Radiol. 2015 Nov;56(11):1293-9. doi: 10.1177/0284185114558973. Epub 2014 Nov 14.

PMID:
25398776
18.

Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.

Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, Nagarajah J, Brandau W, Bockisch A, Rosenbaum-Krumme S.

J Nucl Med. 2014 Nov;55(11):1759-65. doi: 10.2967/jnumed.114.144089. Epub 2014 Oct 20.

19.

Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany.

Farahati J, Nagarajah J, Gilman E, Mahjoob S, Zohreh M, Rosenbaum-Krumme S, Bockisch A, Zakavi SR.

Endocr Pract. 2015 Feb;21(2):122-7. doi: 10.4158/EP14320.OR.

PMID:
25297668
20.

Combined PET imaging and diffusion-weighted imaging of intermediate and high-risk primary prostate carcinomas with simultaneous [18F] choline PET/MRI.

Wetter A, Nensa F, Schenck M, Heusch P, Pöppel T, Bockisch A, Forsting M, Schlosser TW, Lauenstein TC, Nagarajah J.

PLoS One. 2014 Jul 17;9(7):e101571. doi: 10.1371/journal.pone.0101571. eCollection 2014.

21.

Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome.

Köninger A, Koch L, Edimiris P, Enekwe A, Nagarajah J, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.

Arch Gynecol Obstet. 2014 Nov;290(5):1023-30. doi: 10.1007/s00404-014-3317-2. Epub 2014 Jun 25.

PMID:
24961320
22.

Diagnosis of hyperfunctional thyroid nodules: impact of US-elastography.

Ruhlmann M, Stebner V, Görges R, Farahati J, Simon D, Bockisch A, Rosenbaum-Krumme S, Nagarajah J.

Nuklearmedizin. 2014;53(5):173-7. doi: 10.3413/Nukmed-0660-14-04. Epub 2014 Jun 5.

PMID:
24898434
23.

Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.

Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, Fischer HP, Simon B, Höller T, Biersack HJ, Nagarajah J.

J Nucl Med. 2014 Aug;55(8):1260-6. doi: 10.2967/jnumed.114.137166. Epub 2014 May 29.

24.

Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis.

Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Schlosser TW, Pöppel TD, Lauenstein TC, Nagarajah J.

Ann Nucl Med. 2014 Jun;28(5):405-10. doi: 10.1007/s12149-014-0825-x. Epub 2014 Mar 5.

PMID:
24595461
25.

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.

Bauer S, Hilger RA, Mühlenberg T, Grabellus F, Nagarajah J, Hoiczyk M, Reichardt A, Ahrens M, Reichardt P, Grunewald S, Scheulen ME, Pustowka A, Bock E, Schuler M, Pink D.

Br J Cancer. 2014 Mar 4;110(5):1155-62. doi: 10.1038/bjc.2013.826. Epub 2014 Jan 16.

27.

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, Biersack HJ, Nagarajah J, Ezziddin S.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):505-10. doi: 10.1007/s00259-013-2601-x. Epub 2013 Nov 6.

PMID:
24196919
28.

Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT.

Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Altenbernd JC, Schlosser T, Bockisch A, Pöppel T, Lauenstein T, Nagarajah J.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):79-88. doi: 10.1007/s00259-013-2560-2. Epub 2013 Oct 2.

PMID:
24085502
29.

Spatial Reconstruction of Human Thyroid based on Ultrasound and CT Image Data Fusion.

Thiering B, Nagarajah J, Lipinski HG.

Biomed Tech (Berl). 2013 Sep 7. pii: /j/bmte.2013.58.issue-s1-L/bmt-2013-4284/bmt-2013-4284.xml. doi: 10.1515/bmt-2013-4284. [Epub ahead of print] No abstract available.

PMID:
24042919
30.

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.

Wieder HA, Tekin G, Rosenbaum-Krumme S, Klode J, Altenbernd J, Bockisch A, Nagarajah J.

Nuklearmedizin. 2013;52(5):198-203. doi: 10.3413/Nukmed-0584-13-05. Epub 2013 Aug 23.

PMID:
23969722
31.

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.

Kraeber-Bodéré F, Carlier T, Naegelen VM, Shochat E, Lumbroso J, Trampal C, Nagarajah J, Chua S, Hugonnet F, Stokkel M, Gleeson F, Tessier J.

J Nucl Med. 2012 Dec;53(12):1836-46. doi: 10.2967/jnumed.112.109421. Epub 2012 Nov 9.

32.

124I-PET/CT images of differentiated thyroid cancer patients. Distinguishing lymph node metastases from thyroid remnants using kinetic quantities.

Rosenbaum-Krumme S, Nagarajah J, Ruhlmann M, Bockisch A, Jentzen W.

Nuklearmedizin. 2012;51(6):213-6. doi: 10.3413/Nukmed-0481-12-02. Epub 2012 Aug 15.

PMID:
22892653
33.

Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.

Hartung-Knemeyer V, Nagarajah J, Jentzen W, Ruhlmann M, Freudenberg LS, Stahl AR, Bockisch A, Rosenbaum-Krumme SJ.

Ann Nucl Med. 2012 Nov;26(9):723-9. doi: 10.1007/s12149-012-0632-1. Epub 2012 Jul 17.

PMID:
22802008
34.

Estimation of tumour mass in patients with differentiated thyroid carcinoma using serum thyroglobulin.

Rosenbaum-Krumme SJ, Wieduwilt M, Nagarajah J, Bockisch A, Jentzen W.

Nuklearmedizin. 2012;51(6):217-22. doi: 10.3413/Nukmed-0501-12-05. Epub 2012 Jul 6.

PMID:
22773156
35.

Success rate of repeated fine needle aspiration biopsy of clinically suspicious thyroid nodules.

Nagarajah J, Farahati J, Görges R, Grabellus F, Bockisch A, Sheu-Grabellus SY.

Nuklearmedizin. 2012;51(4):116-8. doi: 10.3413/Nukmed-0472-12-01. Epub 2012 May 3.

PMID:
22552740
36.

Pioglitazone therapy in progressive differentiated thyroid carcinoma.

Rosenbaum-Krumme SJ, Bockisch A, Nagarajah J.

Nuklearmedizin. 2012;51(4):111-5. doi: 10.3413/Nukmed-0474-12-01. Epub 2012 Apr 25.

PMID:
22532159
37.

[Influence of the calcitonin assay on the definition of biochemical cure in patients with medullary thyroid carcinoma].

Hartung-Knemeyer V, Müller S, Nagarajah J, Lahner H, Broecker-Preuss M, Bockisch A, Görges R.

Nuklearmedizin. 2012;51(4):125-32. doi: 10.3413/Nukmed-0454-11-12. Epub 2012 Apr 12. German.

PMID:
22526413
38.

Ultrasound-guided fine-needle aspiration biopsy of clinically suspicious thyroid nodules with an automatic aspirator: a novel technique.

Nagarajah J, Sheu-Grabellus SY, Farahati J, Kamruddin KA, Bockisch A, Schmid KW, Görges R.

Thyroid. 2012 Jul;22(7):695-8. doi: 10.1089/thy.2011.0182. Epub 2012 Apr 23.

PMID:
22524469
39.

Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein T, Antoch G, Heusner TA.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):852-63. doi: 10.1007/s00259-012-2077-0. Epub 2012 Mar 6.

PMID:
22392069
40.

18F-fluoride PET/CT for bone scanning. Role of attenuation correction.

Nagarajah J, Dannat T, Hartung V, Bockisch A, Rosenbaum-Krumme S.

Nuklearmedizin. 2012;51(3):84-7. doi: 10.3413/Nukmed-0433-11-10. Epub 2012 Feb 27.

PMID:
22366817
41.

Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging.

Rosenbaum-Krumme SJ, Freudenberg LS, Jentzen W, Bockisch A, Nagarajah J.

Clin Nucl Med. 2012 Mar;37(3):e47-52. doi: 10.1097/RLU.0b013e3182443ca6.

PMID:
22310270
42.

Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.

Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY.

Clin Nucl Med. 2012 Feb;37(2):121-7. doi: 10.1097/RLU.0b013e3182393599.

PMID:
22228332
43.

Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.

Hahn S, Heusner T, Kümmel S, Köninger A, Nagarajah J, Müller S, Boy C, Forsting M, Bockisch A, Antoch G, Stahl A.

Acta Radiol. 2011 Nov 1;52(9):1009-14. doi: 10.1258/ar.2011.100507. Epub 2011 Oct 3.

PMID:
21969709
44.

Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck.

Nagarajah J, Jentzen W, Hartung V, Rosenbaum-Krumme S, Mikat C, Heusner TA, Antoch G, Bockisch A, Stahl A.

Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1862-8. doi: 10.1007/s00259-011-1866-1. Epub 2011 Jul 8.

PMID:
21739331
45.

[Optimization of the fine needle aspiration biopsy (FNAB) of thyroid nodules- automatic aspirator versus manual technique].

Nagarajah J, Sheu-Grabellus SY, Leitzen C, Hartung V, Schmid KW, Bockisch A, Görges R.

Nuklearmedizin. 2011;50(5):189-94. doi: 10.3413/nukmed-0387-11-02. Epub 2011 Jul 5. German.

PMID:
21727989
46.

Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs.

Stahl AR, Heusner TA, Hartung V, Nagarajah J, Bockisch A, Hahn S, Antoch G, Jentzen W.

J Nucl Med. 2011 Jan;52(1):18-23. doi: 10.2967/jnumed.110.077461. Epub 2010 Dec 13.

Supplemental Content

Loading ...
Support Center